Owlet Inc. Expands Horizons with Launch of TGA-Approved Dream Sock™ in Australia and New Zealand
On December 5, 2025, Owlet Inc. (NYSE: OWLT), a pioneering leader in smart infant monitoring, announced a significant expansion of its international footprint. The company has officially launched its Dream Sock™, a pediatric health monitoring device, in Australia and New Zealand, following its approval by Australia’s Therapeutic Goods Administration (TGA). This development marks a strategic move in Owlet's growth plan aimed at providing trusted health monitoring solutions to families across the globe.
1. A Milestone in Pediatric Health Monitoring
The Dream Sock, recognized for its advanced technology, is tailored for infants aged 0-18 months and weighs between 2.5 to 13.6 kg. The device tracks essential vital signs such as pulse rate, oxygen levels, and sleep patterns, providing parents with real-time insights through the Owlet Dream App, available on both iOS and Android platforms. The app, along with the accompanying Base Station, alerts users if any monitored readings fall outside pre-set parameters, combining peace of mind with medical-grade accuracy.
Jonathan Harris, Owlet’s President and CEO, expressed his enthusiasm regarding this international launch, stating, “Bringing Owlet’s TGA-approved pediatric health monitor to Australia and New Zealand represents a meaningful step in our international growth strategy, as parents are actively seeking trusted, medically-validated solutions.”
2. Introducing Owlet360 Subscription Services
In conjunction with the Dream Sock launch, Owlet is also rolling out the Owlet360 subscription service in these markets. This marks the first international rollout of the company's subscription offering. While the core features, including pulse rate and oxygen monitoring, remain available at no cost, Owlet360 enhances the user experience with personalized guidance, expert-backed resources, and comprehensive analytics.
Subscription benefits include daily sleep reports and expanded insights into pulse rate, oxygen levels, movement patterns, comfort temperature, and room environment metrics. This strategic move aligns with Owlet’s objective to diversify its revenue streams and enhance recurring, higher-margin subscription income over time.
3. Availability and Purchase Options
Both the Dream Sock and Owlet360 services are now accessible through Owlet’s e-commerce websites and select retail partners in Australia and New Zealand. The Dream Sock can also be paired with the Company’s Cam® 2, sold as the Dream Duo™, which allows families to monitor their infants' health and well-being more comprehensively.
For those interested in exploring features or making a purchase, Owlet encourages families to visit their websites.
4. Owlet Inc.: A Leader in Pediatric Health Solutions
Owlet, Inc. has established itself as a premier pediatric health platform, known for offering U.S. FDA-cleared and internationally medically-certified wearable monitors. Since its founding in 2012, the company has gained the trust of over 2.5 million parents, creating one of the largest collections of pediatric health and sleep data globally. Owlet is committed to enhancing pediatric wellness by merging cutting-edge medical technology with user-friendly design, fulfilling its mission to give every baby and family the best possible start in life.
As Owlet continues to push the boundaries of innovation in pediatric health monitoring, the launch of the Dream Sock and the expansion of Owlet360 into Australia and New Zealand are expected to significantly bolster its market presence and provide families with the tools they need for informed care decisions.
